Ticker Details
CRISPR Therapeutics AG CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics.
IPO Date:	October 19, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$4.96B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.61 | 2.80%
Avg Daily Range (30 D):	$1.26 | 2.45%
Avg Daily Range (90 D):	$1.37 | 2.56%

Institutional Daily Volume
Avg Daily Volume:	1.21M
Avg Daily Volume (30 D):	1.81M
Avg Daily Volume (90 D):	1.59M

Trade Size
Avg Trade Size (Sh.):	62
Avg Trade Size (Sh.) (30 D):	56
Avg Trade Size (Sh.) (90 D):	51

Institutional Trades
Total Institutional Trades:	6,364
Avg Institutional Trade:	$2.95M
Avg Institutional Trade (30 D):	$2.42M
Avg Institutional Trade (90 D):	$2.96M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$5.66M
Avg Closing Trade (30 D):	$9.5M
Avg Closing Trade (90 D):	$8.93M
Avg Closing Volume:	90.12K

News

Apr 8, 2026 @ 10:30 AM This Biotech Has a Pipeline That Could Redefine It... Source: Prosper Junior Bakiny

Mar 24, 2026 @ 3:05 PM Anti-Aging Protein Research Takes a Step Forward w... Source: Equity-Insider.Com

Mar 23, 2026 @ 5:30 PM CRISPR Therapeutics Stock: Is It a Bargain Buy Rig... Source: David Jagielski, Cpa

Mar 10, 2026 @ 7:23 PM This Is Why CRISPR Therapeutics Stock Is Tumbling ... Source: James Brumley

Mar 4, 2026 @ 6:23 PM Forget CRISPR Therapeutics: This Gene‑Editi... Source: Prosper Junior Bakiny

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-6.47	$-1.35	$-6.47
Diluted EPS	$-6.47	$-1.35	$-6.47
Revenue	$3.51M	$.86M	$3.51M
Gross Profit
Net Income / Loss	$-581.6M	$-130.61M	$-581.6M
Operating Income / Loss	$-664.57M	$-154.76M	$-664.57M
Cost of Revenue
Net Cash Flow	$49.21M	$61.06M	$49.21M
PE Ratio